Actively Recruiting
Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Led by Peking Union Medical College Hospital · Updated on 2024-10-22
30
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study plans to include LARC patients receiving neoadjuvant therapy at this center, conducting PET/CT and PET/MR examinations before treatment, and PET/MR examinations before surgery after neoadjuvant therapy. The changes in the lesion before and after treatment will be compared to evaluate the efficacy of neoadjuvant therapy, including: the relief situation of the rectal primary lesion ; lymph node metastasis; local infiltration around the tumor; peritoneal and other distant metastases , etc. The pathological relief diagnosed by surgical pathology is the gold standard, and the predictive efficacy of PET/MR will be evaluated, comparing the advantages and disadvantages of 18F-FDG and 68Ga-FAPI PET/MR, and comparing with traditional PET/CT and rectal MRI to explore the value of PET/MRI in predicting the efficacy of neoadjuvant therapy in LARC patients.
CONDITIONS
Official Title
Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years old
- ECOG score 0-2
- Pathologically confirmed rectal adenocarcinoma
- Tumor lower edge within 12 cm from the anal edge
- Clinical stage cT3-4N0M0 or cTanyN+M0
- No prior radiotherapy, chemotherapy, or surgery
- Good liver and kidney function, able to tolerate radiotherapy and surgery
- Able to understand the study and provide informed consent
You will not qualify if you...
- ECOG score greater than 2
- Multiple primary colorectal cancers
- History of other malignant tumors within past 5 years (except certain cured or treated cancers)
- Intestinal obstruction, perforation, bleeding, or other emergencies needing surgery
- Pregnant or breastfeeding women
- History of severe mental illness, immune diseases, or hormone medication
- Contraindications for MRI, PET, radiotherapy, immunotherapy, or surgery
- Participation in other clinical studies within last 3 months
- Any other condition deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Z
Zhaoxia huang, B.S.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here